Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL27650730 | 0.82 | ALDH1A1 (0.75) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL28098924 | 0.82 | ALDH1A1 (0.90) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL3137892 | 0.80 | ALDH1A1 (0.60) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL1839538 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL1396421 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL377457 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL190337 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL750993 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL28243758 | 0.78 | ALDH1A1 (0.82) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 | |
| Biphenyl SCHEMBL4002609 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MMP3BCL2L1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-6117885-A | Biphenyl-substituted quinoline derivatives | E. R. SQUIBB & SONS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | AR, NR5A1, BRCA1 | ALDH1A1 2392/4885MMP3 884/4885BCL2L1 433/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | ALDH1A1 2392/4885MMP3 884/4885BCL2L1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.